Trials in Missouri.
44 APOE4-relevant Alzheimer’s trials run in Missouri — 22 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- APOE4 carriers explicitly welcomedNCT04468659AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…
- Part II enrolls APOE4 carriers onlyNCT05386914This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults
This trial is testing whether sirolimus, an FDA-approved drug used in transplant medicine, can improve blood flow to the brain in cognitively healthy adults.…
- Amyloid-focused, drug did not succeedNCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Heart trial, genotype not relevantNCT02884206Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Open to carriers, genotype not trackedNCT03113461MCI: CPAP Treatment of OSA (Memories2)
This trial is testing whether CPAP — the device used to treat sleep apnea — can slow the progression of memory problems in people who already have mild…
- Open to carriers, not 4-specificNCT03507257Longitudinal Early-onset Alzheimer's Disease Study Protocol
LEADS is an observational study, not a treatment trial. Researchers are tracking how early-onset Alzheimer's and related conditions progress over time in…
- Unrelated to APOE4 or Alzheimer'sNCT03744156Sleep and Pain Interventions in Women With Fibromyalgia
This trial is testing whether Cognitive Behavioral Therapy for Insomnia works better than basic sleep hygiene education for women who have both fibromyalgia…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- Open to carriers, not 4-specificNCT04262206Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- PD-focused, genotype not consideredNCT04474379Everyday Memory Impairment in PD-related Cognitive Decline
This trial is testing a behavioral strategy-training program designed to help people with Parkinson's disease manage everyday memory problems. Participants are…
- Not Alzheimer's focused, genotype irrelevantNCT04517552Investigation of Inflammation Using [C-11]-CS1P1
This trial is testing a new PET imaging tool called [11C]-CS1P1, which is designed to measure neuroinflammation in the brain. Researchers want to see if this…
- Caregiver study, genotype not relevantNCT04632628Web-based Cognitive Behavioral Treatment for Insomnia in Dementia Caregivers
This trial is testing a web-based version of Cognitive Behavioral Therapy for Insomnia, called NiteCAPP, designed specifically for family caregivers of people…
- APOE4 results central to studyNCT04699786Returning Research Results That Indicate Risk of Alzheimer Disease Dementia to Healthy Participants in Longitudinal Studies
This trial is studying what happens when researchers share a personalized five-year risk estimate for Alzheimer's dementia with healthy older adults who have…
- Genetic study, carriers likely relevantNCT05010603Late Onset Alzheimer's Disease
This study collects blood samples and runs memory and thinking tests to look for genes that influence who gets Alzheimer's disease. It focuses on families…
- Observational study, genotype not requiredNCT05077579Alzheimer"s Imaging Biomarkers in Obesity
This observational study is looking at whether excess body fat — especially when combined with metabolic problems like high blood sugar or insulin resistance —…
- Imaging study, genotype not requiredNCT05361382Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease
This trial is comparing two different PET scan tracers — Flortaucipir and MK-6240 — that are used to measure tau tangles in the brain, a hallmark of…
- Open to carriers, genotype not requiredNCT05446805Depression and Driving
This study is examining how depression, early Alzheimer's-related brain changes, and antidepressant use affect how older adults drive. Researchers will use PET…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Familial mutation only, not APOE4NCT05552157A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2)…
- Open to carriers, not 4-specificNCT05631236Promoting Cognitive Resilience and Reducing Frailty in Older Veterans With Bright Light Therapy
This trial is testing whether wearing light-emitting glasses in the morning — a technique called bright light therapy — can improve sleep, reduce frailty, and…
- Observational only, genotype not requiredNCT05826457North American Prodromal Synucleinopathy Consortium Stage 2
This study is building a research foundation — enrolling people with REM sleep behavior disorder (RBD) and healthy controls to prepare for future trials of…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Open to carriers, not 4-specificNCT06079190Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing two doses of an experimental drug called GSK4527226 against a placebo in people with early Alzheimer's disease, including those…
- Open to carriers, not 4-specificNCT06274528DORA and LP in Alzheimer's Disease Biomarkers
This Phase 2 trial is testing whether lemborexant, an FDA-approved sleep medication, can lower blood levels of amyloid-beta and tau — two proteins tied to…
- Open to carriers, not 4-specificNCT06585787A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…
- Anti-amyloid combo — carriers face higher ARIA riskNCT06602258A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
This Phase 2 trial is testing whether a drug called E2814, given alongside the already-known anti-amyloid drug lecanemab, can reduce a tau protein marker…
- HIV-specific trial, genotype not relevantNCT06705478Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
This Phase 2 trial is comparing two medications — pramipexole (a dopamine-targeting drug used in Parkinson's and restless legs) and escitalopram (a common…
- Process study, no medical relevanceNCT06804837Implement and Test Visual Consent Template and Process
This trial is testing whether a visual, easier-to-read consent form helps patients better understand what they are agreeing to before joining a research study.…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Open to carriers, not 4-specificNCT07011745A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2)
This trial is testing KarXT plus a new extended-release version called KarX-EC — a non-opioid, non-antipsychotic drug combination — to see whether it reduces…
- Open to carriers, not 4-specificNCT07033494A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
This trial is testing MK-2214, a biological drug designed to slow the spread of tau protein in the brains of people with early Alzheimer's disease. Tau tangles…
- Lifestyle study, genotype not requiredNCT07040904Mindfulness to Enhance Cognitive Health in Latinx Older Adults
This trial is testing whether mindfulness training can support cognitive health in Latinx adults aged 65 and older, with the goal of potentially reducing…
- Genotype not mentioned, proceed cautiouslyNCT07094516A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
This trial is testing VHB937, a biological drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild AD confirmed by…
- Open to carriers, genotype not trackedNCT07120347Remote Sensing for ADRD-Specific Activities Identification in Older Adults
This study puts smart-home sensors and AI into the homes of older adults, some with mild cognitive impairment or early dementia and some without, to see…
- Carriers tracked, ARIA risk significantNCT07169578A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
This trial is testing trontinemab, an anti-amyloid antibody drug, against a placebo in people with early Alzheimer's disease — specifically those at the MCI or…
- Gateway study, genotype not specifiedNCT07177352Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
This is not a treatment trial. It is a pre-screening study run by Roche to figure out who might qualify for their future Alzheimer's disease trials.…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.